


Prasco Lab to market generics version of Colcrlys in US

13 January 2015 | News | By BioSpectrum Bureau

Prasco Lab to market generics version of Colcrlys in US



Singapore: US generics firm, Prasco Laboratories, has entered into alliance with US subsidiary of Japanese pharmaceutical company, Takeda, to distribute Colchicine tablets, the generic version of Colcrlys (colchicine) Tablets in the US.

Colcrlys tablets is indicated for the prophylaxis and treatment of acute gout flares in adults, and the treatment of familial Mediterranean fever (FMF) in adults and children age four or older. Colcrlys is part of Takeda's gout treatment portfolio, and was launched commercially in the US in 2009

Colchicine tablets will be marketed under the Prasco label and will be widely available in US pharmacies beginning later this week.

"Introducing an authorized generic of Colcrlys provides patients, pharmacists, and physicians with access to a therapeutically equivalent option to Colcrlys Tablets for the prevention and treatment of gout flares," stated Mr. Chris Arington, chief executive officer, Prasco.